

What is IMBRUVICA® (ibrutinib)?

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat:

- Adults with Waldenström's macroglobulinemia (WM).

It is not known if IMBRUVICA® is safe and effective in children.

SELECT IMPORTANT SIDE EFFECT INFORMATION

IMBRUVICA® may cause serious side effects, including: bleeding problems (hemorrhage); infections; heart rhythm problems (ventricular arrhythmias, atrial fibrillation, and atrial flutter); heart failure and death; high blood pressure (hypertension); decrease in blood cell counts; second primary cancers; and tumor lysis syndrome (TLS).

Please review the Important Side Effect Information on pages 12 and 13.
Please see the accompanying Important Product Information or go to www.imbruvica.com/prescribing-information.

Welcome to a different way of treating Waldenström's

Starting treatment is an important time in your journey with Waldenström's. This brochure will help you learn more about your condition and how IMBRUVICA® (ibrutinib) may help.[1]

Researchers continue to learn more about how changes in blood cells occur in Waldenström's Macroglobulinemia (WM). These discoveries have helped them develop oral medicines (medicines taken by mouth) such as IMBRUVICA®.[1]

IMBRUVICA® works differently than other treatments such as chemotherapy. For more information on how IMBRUVICA® works, turn to page 10 of this brochure.[1]

With IMBRUVICA®, there's a once-daily oral treatment option available to treat Waldenström's[1]

IMBRUVICA® is a prescription medicine used to treat adults with Waldenström's Macroglobulinemia.

It is not known if IMBRUVICA® is safe and effective in children.

IMPORTANT SIDE EFFECT INFORMATION (CONT'D)

IMBRUVICA® may cause serious side effects, including:

- Bleeding problems (hemorrhage)
- Infections
- Heart rhythm problems (ventricular arrhythmias, atrial fibrillation, and atrial flutter); heart failure and death
- High blood pressure (hypertension)
- Decrease in blood cell counts
- Second primary cancers
- Tumor lysis syndrome (TLS)

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Please review the Important Side Effect Information on pages 12 and 13.
Please see the accompanying Important Product Information or go to www.imbruvica.com/prescribing-information.

The information in this brochure is not intended to replace the advice of your doctor. If you have any questions about your IMBRUVICA® treatment, be sure to contact your healthcare team.

TABLE OF CONTENTS

Understanding Waldenström's[2]

Everyone reacts to the news that they have cancer in their own way. It's normal to feel overwhelmed. Learning about Waldenström's is one step that may help you feel more at ease.

Waldenström's is a rare type of lymphoma that usually progresses slowly. In Waldenström's, cancer occurs in B cells, a type of white blood cell. B cells are an important part of your immune system, which defends your body against infection.

In Waldenström's, abnormal B cells grow out of control and may crowd out healthy cells in your **bone marrow, lymph nodes, spleen,** and other organs. It can also cause high levels of abnormal immunoglobulin M (**IgM**).

High levels of abnormal IgM can make your blood too thick, causing many Waldenström's symptoms. When your blood becomes too thick, it causes a syndrome called **hyperviscosity**.

Lymph nodes[3]
These glands contain immune cells that fight infections

Bone marrow[3]
This is the soft inner part of bones where most blood cells are made

Spleen[3]
This organ helps make and remove blood cells. It's found next to the stomach

IgM[3]
A blood protein that normally helps your body fight infection. Abnormal IgM does not fight infection

Please review the Important Side Effect Information on pages 12 and 13.
Please see the accompanying Important Product Information or go to www.imbruvica.com/prescribing-information.

What are common symptoms of Waldenström's?[2,4,5]

Some people with Waldenström's are asymptomatic at the time of diagnosis. As the disease progresses, people may experience one or more of the following common symptoms.



How you feel matters

Only you know how you are feeling. If you're feeling mentally or physically tired, or experience any of the symptoms mentioned here, talk to your doctor. It's especially important to reach out to your doctor if you experience the following symptoms:

"B" symptoms[2]:	Symptoms related to high levels of IgM[2]:	
• Chills • Fever • Unexpected weight loss	• Confusion • Blurry vision or vision problems • Dizziness • Headache	• Slurred speech • Weakness on one side of the body

People who took IMBRUVICA® had more time without disease progression or death[1]

This clinical trial of 150 people included those who had been previously treated for Waldenström's, as well as those who had never received treatment before. Half received IMBRUVICA® plus rituximab. The remaining half received rituximab alone.

- People who took IMBRUVICA® + rituximab were 75% less likely to have their disease worsen or die compared to those taking rituximab alone
  - With an overall follow-up of 63 months, 29% of those taking IMBRUVICA® + rituximab had their disease worsen or died compared to 67% of people taking rituximab
- Adding IMBRUVICA® to rituximab more than doubled patient response rates compared with just rituximab (76% response rate for IMBRUVICA® + rituximab vs 31% for rituximab)

IMBRUVICA® has helped many people with previously treated Waldenström's[1,6,7]

IMBRUVICA® has been studied on its own (as a single agent) in people who had received at least one prior Waldenström's treatment.

In a clinical trial of 63 people with previously treated Waldenström's:

- 62% (39 people) treated with IMBRUVICA® had a response. After treatment, their doctor observed fewer signs of the disease as seen through blood tests, CT scans, and/or bone marrow tests
- The median* amount of time to respond to IMBRUVICA® treatment was 1.2 months

In a separate study of 31 people with previously treated Waldenström's:

- With an overall follow-up of 61 months, 77% (24 people) treated with IMBRUVICA® had a response

IMPORTANT SIDE EFFECT INFORMATION (CONT'D)

IMBRUVICA® may cause serious side effects, including:

- **Bleeding problems (hemorrhage) are common** during treatment with IMBRUVICA®, and can also be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding, or bleeding that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in your speech, or a headache that lasts a long time or severe headache.

What you should know about the side effects of IMBRUVICA® (ibrutinib)[1]

IMBRUVICA® can cause serious side effects, including:

- Bleeding problems (hemorrhage)
- Infections
- Heart rhythm problems (ventricular arrhythmias, atrial fibrillation, and atrial flutter); heart failure and death
- High blood pressure (hypertension)
- Decrease in blood cell counts
- Second primary cancers
- Tumor lysis syndrome (TLS)*

*TLS is a disorder caused by the breakdown products of cancer cells, which can lead to kidney failure and other abnormalities.

Across two Waldenström's Macroglobulinemia (WM) clinical trials of previously treated patients taking IMBRUVICA® only, the most common side effects were:

- Low white blood cell count
- Diarrhea
- Low platelet count
- Bruising
- Bleeding
- Low red blood cell count
- Muscle and bone pain
- Nausea
- Rash
- Tiredness

What you need to know about the side effects of IMBRUVICA® plus rituximab[1]

The most common side effects of IMBRUVICA® plus rituximab among previously treated patients and those who had never received treatment before are:

- Bruising
- Muscle and bone pain
- Bleeding
- Diarrhea
- Joint pain
- Rash
- Nausea
- High blood pressure

This is not a complete list of side effects. Others may occur. Tell your doctor if you think you are experiencing side effects.

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Please review the Important Side Effect Information on pages 12 and 13.
Please see the accompanying Important Product Information or go to www.imbruvica.com/prescribing-information.

Helpful tips for Waldenström's patients taking IMBRUVICA®

You may experience side effects while taking IMBRUVICA®.[1] The suggestions below may help you while on IMBRUVICA®. Talk to your healthcare provider if you think you are experiencing any side effects.

Tips to help with diarrhea[8]:

- Stay hydrated. Drink fluids such as water, decaffeinated tea, and clear broth
- Eat small meals often, and avoid very hot or spicy foods
- Avoid greasy foods, bran, raw fruits and vegetables, caffeine, and alcohol

To help reduce tiredness[9]:

- Balance periods of light movement with periods of rest
- Get plenty of sleep, which may include short naps
- Remain well hydrated throughout the day
- Eat a well-balanced diet that includes protein

To help reduce infection[10]:

- Wash hands often and bathe every day
- Avoid crowds and individuals with contagious diseases
- Do not keep fresh flowers or live plants in your living space
- Do not clean up droppings from your pets, have someone else do this for you

Infection is a serious possible side effect of IMBRUVICA®. Notify a healthcare professional immediately if signs of infection (eg, fever, chills, weakness, and confusion) occur.[1]

IMBRUVICA® (ibrutinib) is an oral Waldenström's medicine taken once a day. It works differently than chemotherapy[1]

- Bruton's tyrosine kinase (***BTK***) is a protein found in your B cells. It sends "signals" that help B cells stay alive and multiply
- IMBRUVICA® works by blocking a protein in your cells called BTK. This action helps stop B cells from surviving and multiplying
- IMBRUVICA® may slow the spread of Waldenström's

Because of how IMBRUVICA® works, it may cause side effects. A relationship between how IMBRUVICA® works and why it helps to treat Waldenström's has not been clearly identified.

IMBRUVICA® was the first FDA-approved treatment for Waldenström's. Please talk to your doctor about whether IMBRUVICA® is right for you.[11]

IMPORTANT SIDE EFFECT INFORMATION (CONT'D)

IMBRUVICA® may cause serious side effects, including:

- **Infections** can happen during treatment with IMBRUVICA®. These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA®.
- **Heart problems.** Serious heart rhythm problems (ventricular arrhythmias, atrial fibrillation and atrial flutter), heart failure and death have happened in people treated with IMBRUVICA®, especially in people who have an infection, an increased risk for heart disease, or have had heart rhythm problems in the past. Your heart function will be checked before and during treatment with IMBRUVICA®. Tell your healthcare provider if you get any symptoms of heart problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, swelling of the feet, ankles or legs, chest discomfort, or you faint. If you develop any of these symptoms, your healthcare provider may do tests to check your heart and may change your IMBRUVICA® dose.
- **High blood pressure (hypertension).** New or worsening high blood pressure has happened in people treated with IMBRUVICA®. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure.
- **Decrease in blood cell counts.** Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA®, but can also be severe. Your healthcare provider should do monthly blood tests to check your blood counts.

Get the most out of your visits by asking questions

You may have questions about your treatment plan.

Remember to add your questions to your journal. If you don't have a journal yet, you can add notes to the space provided on pages 22-23.

If you are unsure what to ask, consider adding these:

- How will I know if my treatment is working?

_____

- What kinds of side effects should I expect with my treatment?

_____

- What should I do if I have side effects?

_____

- Is my experience what you usually see in other patients with Waldenström's?

_____

- How will I know if my Waldenström's is getting worse?

_____

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Please review the Important Side Effect Information on pages 12 and 13. Please see the accompanying Important Product Information or go to www.imbruvica.com/prescribing-information.

IMPORTANT SIDE EFFECT INFORMATION

What is IMBRUVICA® (ibrutinib)?

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat:

- Adults with Waldenström's macroglobulinemia (WM).

It is not known if IMBRUVICA® is safe and effective in children.

Before taking IMBRUVICA®, tell your healthcare provider about all of your medical conditions, including if you:

- have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA® for any planned medical, surgical, or dental procedure.
- have bleeding problems
- have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high cholesterol, or diabetes
- have an infection
- have liver problems
- are pregnant or plan to become pregnant. IMBRUVICA® can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with IMBRUVICA®. Tell your healthcare provider if you are pregnant or think you may be pregnant during treatment with IMBRUVICA®.
  - **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with IMBRUVICA® and for 1 month after the last dose.
  - **Males** with female partners who are able to become pregnant should use effective birth control, such as condoms, during treatment with IMBRUVICA® and for 1 month after the last dose.
- are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with IMBRUVICA® and for 1 week after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.

How should I take IMBRUVICA®?

- Take IMBRUVICA® exactly as your healthcare provider tells you to take it.
- Take IMBRUVICA® 1 time a day at about the same time each day.

IMBRUVICA® comes as capsules or tablets.

- **If your healthcare provider prescribes IMBRUVICA® capsules or tablets:**
  - Swallow IMBRUVICA® capsules or tablets whole with a glass of water.
  - Do not open, break, or chew IMBRUVICA® capsules.
  - Do not cut, crush, or chew IMBRUVICA® tablets.
- If you miss a dose of IMBRUVICA® take it as soon as you remember on the same day. Take your next dose of IMBRUVICA® at your regular time on the next day. Do not take extra doses of IMBRUVICA® to make up for a missed dose.
- If you take too much IMBRUVICA® call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking IMBRUVICA®?

- You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) during treatment with IMBRUVICA®. These products may increase the amount of IMBRUVICA® in your blood.

What are the possible side effects of IMBRUVICA® (ibrutinib)?

IMBRUVICA® may cause serious side effects, including:

- **Bleeding problems (hemorrhage) are common** during treatment with IMBRUVICA®, and can also be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding, or bleeding that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in your speech, or a headache that lasts a long time or severe headache.
- **Infections** can happen during treatment with IMBRUVICA®. These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA®.
- **Heart problems.** Serious heart rhythm problems (ventricular arrhythmias, atrial fibrillation and atrial flutter), heart failure and death have happened in people treated with IMBRUVICA®, especially in people who have an infection, an increased risk for heart disease, or have had heart rhythm problems in the past. Your heart function will be checked before and during treatment with IMBRUVICA®. Tell your healthcare provider if you get any symptoms of heart problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, swelling of the feet, ankles or legs, chest discomfort, or you faint. If you develop any of these symptoms, your healthcare provider may do tests to check your heart and may change your IMBRUVICA® dose.
- **High blood pressure (hypertension).** New or worsening high blood pressure has happened in people treated with IMBRUVICA®. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure.
- **Decrease in blood cell counts.** Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA®, but can also be severe. Your healthcare provider should do monthly blood tests to check your blood counts.
- **Second primary cancers.** New cancers have happened during treatment with IMBRUVICA®, including cancers of the skin or other organs.
- **Tumor lysis syndrome (TLS).** TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.

The most common side effects of IMBRUVICA® in adults with B-cell malignancies (CLL/SLL and WM) include:

- diarrhea
- tiredness
- muscle and bone pain
- rash
- bruising
- nausea

Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.

These are not all the possible side effects of IMBRUVICA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of IMBRUVICA®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it was not prescribed. Do not give IMBRUVICA® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA® that is written for health professionals.

Please see the full Important Product Information or go to www.imbruvica.com/prescribing-information.

Distributed and Marketed by: Pharmacyclics LLC Sunnyvale, CA USA 94085
Marketed by: Janssen Biotech, Inc. Horsham, PA USA 19044. For more information call 1-877-877-3536.

Take it anywhere, once a day[1]

IMBRUVICA® (ibrutinib) is an oral treatment that gives you the freedom to take it at home or anywhere you might be. For Waldenström's, IMBRUVICA® is dosed once a day as either a single 420-mg tablet or three 140-mg capsules. Talk to your doctor about which dosing option is right for you.

IMBRUVICA® tablets come in a blister pack

- **Take one 420-mg IMBRUVICA® tablet by mouth,** at about the same time each day with a glass of water

OR

IMBRUVICA® capsules come in a bottle

- **Take all three 140-mg IMBRUVICA® capsules by mouth,** at about the same time each day with a glass of water

Tablets and capsules are not shown at actual size.

How to take IMBRUVICA®[1]

- Do not cut, crush or chew IMBRUVICA® tablets. Do not open, break or chew IMBRUVICA® capsules
- If you miss a dose of IMBRUVICA®, take it as soon as you remember on the same day
  - Take your next dose of IMBRUVICA® at your regular time on the next day
  - Do not take extra doses of IMBRUVICA® to make up for a missed dose
- If you take too much IMBRUVICA®, call your healthcare provider or go to the nearest hospital emergency room right away
- Call your doctor or pharmacist if you have any questions

Tell your doctor about any other medications you are taking, including prescriptions or over-the-counter medications, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.

Store IMBRUVICA® in its original container at room temperature from 68°F to 77°F (20°C to 25°C).

Do not stop taking IMBRUVICA® without talking to your doctor. Always take IMBRUVICA® exactly as your doctor prescribes.

Please review the Important Side Effect Information on pages 12 and 13.

Please see the accompanying Important Product Information or go to www.imbruvica.com/prescribing-information.

While taking IMBRUVICA®[1]

imbruvica® (ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

- Do not drink grapefruit juice
- Do not eat grapefruit
- Do not eat Seville oranges, often used in marmalade

These products may increase the amount of IMBRUVICA® in your blood.

Strategies to help you plan your IMBRUVICA® routine[12,13]

It's important to take your medicines exactly as directed by your doctor. Creating a routine can help you remember. This will help you get the most benefit from your treatment.

Link it. Take your medicine at the same time as something else you do on a daily basis, like walking the dog or brushing your teeth.

See it. Use reminder notes or put your IMBRUVICA® container in a place you will see it (like next to your bed). Keep IMBRUVICA® out of the reach of children.

Hear it. Set a daily alarm on your phone, watch, or clock to go off when you need to take IMBRUVICA®.

Use your tools. Use tools, such as an app on your smartphone or a calendar, to set reminders for yourself.

Do not stop taking IMBRUVICA® without talking to your doctor. Always take IMBRUVICA® exactly as your doctor prescribes.



imbruvica®
By Your Side
Patient Support

Discover personalized one-on-one support

When starting a new treatment like IMBRUVICA® you may have questions. That's why we created **IMBRUVICA® By Your Side,*** to help you every step of the way.

*IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to always talk to their healthcare provider and treatment team about any medical decisions and concerns they may have.

IMBRUVICA® By Your Side Ambassadors†

- Speak to your own, dedicated ambassador each time you call throughout your treatment journey
- One-on-one support to help you stay on track with your prescribed treatment plan
- Receive help developing routines and understanding treatment costs

Insurance Specialists

- Guide you through the insurance process
- Identify potential savings on the cost of your prescription
- Explain the role of specialty pharmacies

Financial Assistance

- Support for federally funded Medicare, Medicaid, and other government insurance plans
- Patients on commercial insurance may be eligible to pay as little as $0 per prescription‡ with their IMBRUVICA® Copay Card

For more in-depth information, visit **ImbruvicaByYourSide.com** or call **1-888-YourSide (1-888-968-7743) Monday-Friday,** 8AM - 8PM ET

†By Your Side Ambassadors are provided by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie Company and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

‡Eligibility: Available to patients with commercial insurance coverage for IMBRUVICA® (ibrutinib) who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit https://www.imbruvica.com/imbruvica-by-your-side or call 1-888-968-7743 for additional information. For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit https://www.pharmacyclics.com/privacy-notice.html#info_pcp.

imbruvica®
(ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

Please review the Important Side Effect Information on pages 12 and 13.
Please see the accompanying Important Product Information or go to www.imbruvica.com/prescribing-information.

Remember, you are the most important person on your healthcare team. Staying informed and motivated will help you advocate for your own care.

Please review the Important Side Effect Information on pages 12 and 13.
Please see the accompanying Important Product Information or go to www.imbruvica.com/prescribing-information.

Stay motivated

You are not alone. Surround yourself with friends, family, and support groups in order to stay motivated. One-on-one peer support programs, such as the Lymphoma Support Network (www.lymphoma.org), match lymphoma survivors and caregivers with volunteers who have gone through similar experiences.

Your family and friends may want to support you, but they might not know how. Make sure to tell them exactly how they can help. You might ask a friend or family member to:

- Be with you at doctor appointments
- Go grocery shopping for you or with you
- Do something fun to help you stay positive

Stay informed

Knowledge is empowering—so try to learn all you can about your condition. The websites below are a good place to find additional information on Waldenström's, treatment options, support groups, and resources:

For more information on Waldenström's

International Waldenström's Macroglobulinemia Foundation	www.iwmf.com
American Cancer Society	www.cancer.org
Leukemia & Lymphoma Society	www.lls.org
Lymphoma Research Foundation	www.lymphoma.org

For cancer support communities

The Advocacy Connector	www.advocacyconnector.com
Association of Community Cancer Centers (ACCC)	www.accc-cancer.org
CancerCare	www.cancercare.org
Cancer Support Community	www.cancersupportcommunity.org
Cancer Updates, Research & Education (CURE)	www.curetoday.com
Patient Advocate Foundation	www.patientadvocate.org
Patient Empowerment Network	www.powerfulpatients.org

Suggested reading

Below are some websites you may want to investigate to learn more about Waldenström's.

Genetics Home Reference: The National Institutes of Health provides a searchable database of information about cancer and cancer genetics. Visit ghr.nlm.nih.gov.

NCI Dictionary of Cancer Terms: This National Institutes of Health dictionary provides simple definitions of more than 8000 cancer terms. Visit www.cancer.gov and click on "Dictionary."

Visit your local library to find other resources. Your reference librarian can also help you access online services. These services can allow you to use your library card to borrow books and other resources without leaving your home by downloading them to your smartphone, tablet, or computer.

References: 1. IMBRUVICA® (ibrutinib) Prescribing Information. **2.** American Cancer Society. Waldenstrom Macroglobulinemia. https://www.cancer.org/cancer/types/waldenstrom-macroglobulinemia.html. Accessed August 21, 2023. **3.** National Cancer Institute. NCI dictionary of cancer terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed August 21, 2023. **4.** Paludo J, Ansell SM. Waldenström macroglobulinemia: biology, genetics, and therapy. *Blood Lymphat Cancer*. 2016;6:49-58. **5.** García-Sanz R, Montoto S, Torrequebrada A, et al. Waldenström macroglobulinemia: presenting features and outcome in a series with 217 cases. *Brit J Haematol*. 2001;115(3): 575-582. **6.** Kimby E, Treon SP, Anagnostopoulos A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenström's Macroglobulinemia. *Clin Lymphoma Myeloma*. 2006;6:380-383. **7.** Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. *N Engl J Med*. 2018;378(25):2399-2410. **8.** American Cancer Society. Getting help for diarrhea. https://www.cancer.gov/about-cancer/treatment/side-effects/diarrhea. Updated September 24, 2021. Accessed August 21, 2023. **9.** American Cancer Society. Managing cancer-related fatigue. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/fatigue/managing-cancer-related-fatigue.html. Updated February 1, 2020. Accessed August 21, 2023. **10.** American Cancer Society. Preventing infections in people with cancer. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/infections/preventing-infections-in-people-with-cancer.html. Updated April 10, 2020. Accessed August 21, 2023. **11.** Raedler LA. Imbruvica (ibrutinib): first drug approved for the treatment of patients with Waldenström's Macroglobulinemia. *Am Health Drug Benefits*. 2016;9:89-92. **12.** Borgsteede SD, Westerman MJ, Kok IL, Meeuse JC, de Vries TPGM, Hugtenburg JG. Factors related to high and low levels of drug adherence according to patients with type 2 diabetes. *Int J Clin Pharm*. 2011;33(5):779-787. **13.** National Institutes of Health MedlinePlus. Taking medicine at home—create a routine. http://www.nlm.nih.gov/medlineplus/ency/patientinstructions/000613.htm. Updated August 15, 2022. Accessed August 21, 2023.

Please review the Important Side Effect Information on pages 12 and 13.
Please see the accompanying Important Product Information or go to www.imbruvica.com/prescribing-information.

Notes

IMBRUVICA® was the first FDA-approved treatment for Waldenström's[1]

Ask your doctor if IMBRUVICA® is right for you.

What is IMBRUVICA®?

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat:

- Adults with Waldenström's macroglobulinemia (WM).

It is not known if IMBRUVICA® is safe and effective in children.

Reference: 1. IMBRUVICA® (ibrutinib) Prescribing Information.

To learn more,
visit **www.IMBRUVICA.com/WM**
or call **1-877-877-3536**

imbruvica®
(ibrutinib)
420, 280, 140 mg tablets | 140, 70 mg capsules

SELECT IMPORTANT SIDE EFFECT INFORMATION

IMBRUVICA® may cause serious side effects, including: bleeding problems (hemorrhage); infections; heart rhythm problems (ventricular arrhythmias, atrial fibrillation, and atrial flutter); heart failure and death; high blood pressure (hypertension); decrease in blood cell counts; second primary cancers; and tumor lysis syndrome (TLS).

Please review the Important Side Effect Information on pages 12 and 13.
Please see the accompanying Important Product Information or go to www.imbruvica.com/prescribing-information.

pharmacyclics®
An AbbVie Company

janssen